Advanced search
Publication Cover
Expert Review of Vaccines Volume 6, 2007 - Issue 2
Submit an article Journal homepage
439
Views
149
CrossRef citations to date
0
Altmetric
Vaccine Profile

New hepatitis B vaccine formulated with an improved adjuvant system

Michael Kundi Professor, Center for Public Health, Medical University of Vienna, Kinderspitalgasse 15, 1095 Vienna, Austria. [email protected]
Pages 133-140 | Published online: 09 Jan 2014

References

  • Alter MJ. Epidemiology of hepatitis B in Europe and worldwide. J. Hepatol.39(Suppl. 1), S64–S69 (2003).
  • Maddrey WC. Hepatitis B – an important public health issue. Clin. Lab.47, 51–55 (2001).
  • Van Damme P, Kane M, Meheus A. Integration of hepatitis B vaccination into national immunisation programmes. Viral Hepatitis Prevention Board. Br. Med. J.314, 1033–1036 (1997).
  • Shepard CW, Simard EP, Finelli L et al. Hepatitis B virus infection: epidemiology and vaccination. Epidemiol. Rev.28, 112–125 (2006).
  • Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J. Viral Hepat.11, 97–107 (2004).
  • Custer B, Sullivan SD, Hazlet TK et al. Global epidemiology of hepatitis B virus. J. Clin. Gastroenterol.38(Suppl. 3), S158–S168 (2004).
  • Lurman A. Eine Ikterus Epidemie. Berl. Klin. Wochenschr.22, 20–23 (1885).
  • Blumberg BS, Alter HL, Visnich S. A “new” antigen in leukemia sera. JAMA191, 541–546 (1965).
  • Beasley P. Hepatitis B virus: the major etiology of hepatocellular carcinoma. Cancer61, 1942–1956 (1988).
  • WHO. Hepatitis B vaccines. Wkly Epidemiol. Rec.79, 255–263 (2004).
  • Advisory Committee on Immunization Practices (ACIP). A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States. MMWR Recomm. Rep.54, 1–31 (2005).
  • Andre FE. Overview of a 5-year clinical experience with a yeast-derived hepatitis B vaccine. Vaccine8(Suppl.), S74–S78 (1990).
  • Bauer T, Jilg W. Hepatitis B surface antigen-specific T and B cell memory in individuals who had lost protective antibodies after hepatitis B vaccination. Vaccine24, 572–577 (2006).
  • Watson B, West DJ, Chilkatowsky A, Piercy S, Ioli V. Persistence of immunologic memory for 13 years in recipients of a recombinant hepatitis B vaccine. Vaccine19, 3164–3268 (2001).
  • Jilg W, Schmidt M, Zachoval R, Deinhart F. Persistenz von Antikoerpern gegen Hepatatis-B-Oberflaechenantigen nach Impfung gegen Hepatitis B. Dtsch Med. Wochenschr.110, 205–209 (1985).
  • Scheiermann N, Gesemann M, Maurer C et al. Persistence of antibodies after immunization with a recombinant yeast-derived hepatitis B vaccine following two different schedules. Vaccine8(Suppl.), S44–S46 (1990).
  • Just M, Berger RM, Scheiermann N. Persistence of antibodies following vaccination with a yeast-derived recombinant hepatitis B vaccine. Vaccine6, 401–402 (1988).
  • Ambrosch F, Frisch-Niggemeyer W, Kremsner P et al. Persistence of vaccine-induced antibodies to hepatitis surface antigen and the need for booster vaccination in adult subjects. Postgrad. Med. J.63, 129–135 (1987).
  • Grob PJ, Dufek A, Joller-Jemelka HI. Hepatatis-B-Impfung – wann ist eine Booster-Injektion noetig? Schweiz Med. Wochenschr.115, 394–402 (1985).
  • Watson B, West DJ, Chilkatowsky A et al. Persistence of immunologic memory for 13 years in recipients of a recombinant hepatitis B vaccine. Vaccine19, 3164–3168 (2001).
  • Van Damme P, Leroux-Roels G, Law B et al. Long-term persistence of antibodies by vaccination and safety follow-up, with the first combined vaccine against hepatitis A and B in children and adults. J. Med. Virol.65, 6–13 (2001).
  • Williams IT, Goldstein ST, Tufa J et al. Long term antibody response to hepatitis B vaccination beginning at birth and to subsequent booster vaccination. Pediatr. Infect. Dis. J.22, 157–163 (2003).
  • Zanetti AR, Mariano A, Romano L et al. Long term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. Lancet366, 1379–1384 (2005).
  • Van Herck K, Van Damme P, Thoelen S, Meheus A. Long-term persistence of anti-HBs after vaccination with a recombinant DNA yeast derived hepatitis B vaccine: 8 year results. Vaccine16, 1933–1935 (1998).
  • Fitzsimons D, Francois G, Hall A et al. Long-term efficacy of hepatitis B vaccine, booster policy, and impact of hepatitis B virus mutants. Vaccine23, 4158–4166 (2005).
  • Coates T, Wilson R, Patrick G et al. Hepatitis B vaccines: assessment of the seroprotective efficacy of two recombinant DNA vaccines. Clin. Ther.23, 392–403 (2001).
  • Stoffel M, Lievens M, Dieussaert I, Martin I, André F. Immunogenicity of Twinrix in older adults: a critical analysis. Expert Rev. Vaccines2(1), 9–14 (2003).
  • Fisman DN, Agrawal D, Leder K. The effect of age on immunologic response to recombinant hepatitis B vaccine: a metaanalysis. Clin. Infect. Dis.35, 1368–1375 (2002).
  • CDC. Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR50, 1–43 (2001).
  • Fabrizi F, Bunnapradist S, Martin P. HBV infection in patients with end-stage renal disease. Semin. Liver Dis.24(Suppl. 1), 63–70 (2004).
  • McNulty CA, Bowen JK, Williams AJ. Hepatitis B vaccination in predialysis chronic renal failure patients a comparison of two vaccination schedules. Vaccine23, 4142–4147 (2005).
  • Rosen FS, Steiner LA, Unanue ER. Dictionary of Immunology. The Macmillan Press Ltd, London, UK (1989).
  • Glenny AT, Pope CG, Waddington H, Wallace U. Immunological notes. XXIII. The antigenic value of toxoid precipitated by potassium alum. J. Pathol. Bacteriol.29, 38–39 (1926).
  • Brewer JM. (How) do aluminium adjuvants work? Immunol. Lett.102, 10–15 (2006).
  • Mueller DL, Jenkins MK, Schwartz RH. Clonal expansion versus clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. Annu. Rev. Immunol.7, 481–511 (1989).
  • Sporri R, Reis e Sousa C. Inflammatory mediators are insufficient for full dendritic cell activation and promote expansion of CD4+ T cell populations lacking helper function. Nat. Immunol.6, 163–170 (2005).
  • Menges M, Rossner S, Voigtlander C et al. Repetitive injections of dendritic cells matured with tumor necrosis factor alpha induce antigen-specific protection of mice from autoimmunity. J. Exp. Med.195, 15–21 (2002).
  • Gupta RK, Relyveld EH, Lindblad EB et al. Adjuvants – a balance between toxicity and adjuvanticity. Vaccine11, 293–306 (1993).
  • Ribi E, Amano K, Cantrell JL et al. Preparation and antitumor activity of nontoxic lipid A. Cancer Immunol. Immunother.12, 91–96 (1982).
  • Qureshi N, Takayama K, Ribi E. Purification and structural determination of nontoxic lipid A obtained from lipopolysaccharide of Salmonella typhimurium. J. Biol. Chem.257, 11808–11815 (1982).
  • Takayama K, Qureshi N, Ribi E, Cantrell JL. Separation and characterization of toxic and nontoxic forms of lipid A’s. Rev. Infect. Dis.6, 439–443 (1983).
  • Ribi E, Cantrell JL, Feldner T. Biological activities of monophosphoryl lipid A. In: Microbiology. Levine L, Bonventre PF, Morello JA (Eds). Washington, DC, USA, 9–13 (1986).
  • Myers KR, Truchot AT, Ward J. A critical determinant of lipid A endotoxic activity. In: Proceedings of the first Congress of the International Endotoxin Society on Cellular and Molecular Aspects of Endotoxin Reactions. Nowotny A (Ed.). Elsevier, Amsterdam, The Netherlands, 145–156 (1990).
  • Thoelen S, De Clercq N, Tornieporth N. A prophylactic hepatitis B vaccine with a novel adjuvant system. Vaccine19, 2400–2403 (2001).
  • Brunkhorst R, Lufft V, Dannenberg B et al. Improved survival in patients with type 1 diabetes mellitus after renal transplantation compared with hemodialysis: a case-control study. Transplantation76, 115–119 (2003).
  • Locatelli F, Pozzoni P, Del Vecchio L. Renal replacement therapy in patients with diabetes and end-stage renal disease. J. Am. Soc. Nephrol.15(Suppl. 1), S25–S29 (2004).
  • Ansell D, Feest T. The sixth annual report, The UK Renal Registry, Bristol, UK (2003).
  • Girndt M, Kohler H. Hepatitis B virus infection in hemodialysis patients. Semin. Nephrol.22, 340–350 (2002).
  • Zacks SL, Fried MW. Hepatitis B and C and renal failure. Infect. Dis. Clin. North Am.15, 877–899 (2001).
  • Tokars JI, Finelli L, Alter MJ et al. National surveillance of dialysis-associated diseases in the United States, 2001. Semin. Dial.17, 310–319 (2004).
  • Burdick RA, Bragg-Gresham JL, Woods JD et al. Patterns of hepatitis B prevalence and seroconversion in hemodialysis units from three continents: the DOPPS. Kidney Int.63, 2222–2229 (2003).
  • CDC. Outbreaks of hepatitis B virus infection among hemodialysis patients – California, Nebraska, and Texas, 1994. MMWR45, 285–289 (1996).
  • Igaki N, Nakaji M, Moriguchi R et al. An outbreak of fulminant hepatitis B in immunocompromised hemodialysis patients. J. Gastroenterol.38, 968–976 (2003).
  • European Best Practice Guidelines for Haemodialysis (Part I); Section VI: Haemodialysis-associated infection, VI.6 Prevention and management of HBV, HCV and HIV in HD patients. Nephrol. Dial. Transplant.17(Suppl. 7), 78–81 (2002).
  • Agarwal SK, Irshad M, Dash SC. Comparison of two schedules of hepatitis B vaccination in patients with mild, moderate and severe renal failure. J. Assoc. Physicians India47, 183–185 (1999).
  • DaRoza G, Loewen A, Djurdjev O et al. Stage of chronic kidney disease predicts seroconversion after hepatitis B immunization: earlier is better. Am. J. Kidney Dis.42, 1184–1192 (2003).
  • Kane M, Banatvala J, Van Damme P et al. Are booster immunisations needed for lifelong hepatitis B immunity? European Consensus Group on Hepatitis B Immunity. Lancet355, 561–565 (2000).
  • Thoelen S, Van Damme P, Mathei C et al. Safety and immunogenicity of a hepatitis B vaccine formulated with a novel adjuvant system. Vaccine16, 708–714 (1998).
  • Ambrosch F, Wiedermann G, Kundi M et al. A hepatitis B vaccine formulated with a novel adjuvant system. Vaccine18, 2095–2101 (2000).
  • Levie K, Gjorup I, Skinhoj P et al. A 2-dose regimen of a recombinant hepatitis B vaccine with the immune stimulant AS04 compared with the standard 3-dose regimen of Engerix-B in healthy young adults. Scand. J. Infect. Dis.34, 610–614 (2002).
  • Desombere I, Van der Wielen M, Van Damme P et al. Immune response of HLA DQ2 positive subjects, vaccinated with HBsAg/AS04, a hepatitis B vaccine with a novel adjuvant. Vaccine20, 2597–2602 (2002).
  • Van Herck K, Law B, Diaz-Mitoma F et al. Immunogenicity and reactogenicity of the novel adjuvanted hepatitis B vaccine (HBsAg/SBAS4), compared to that of Engerix-B™ in older adults aged 50–70 years. Antiviral Ther.5, 4 (2000).
  • Boland G, Beran J, Lievens M et al. Safety and immunogenicity profile of an experimental hepatitis-B vaccine adjuvanted with AS04. Vaccine23, 316–320 (2004).
  • Norella Kong CT, Beran J, Kee SA et al. Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-haemodialysis and haemodialysis patients. Kidney Int.68, 2298–2303 (2005).
  • Norella Kong CT, Beran J, Kee SA et al. Persistence of anti-HBs antibody seroprotection rates and safety of an adjuvanted hepatitis B vaccine in pre-haemodialysis and haemodialysis patients. ISVHLD July 1–5, Paris, France, P523 (2006).

Websites

  • WHO. Hepatitis B factsheet, 2000. http://www.who.int/mediacentre/factsheet/fs204/en/index.html
  • CDC. Geographic distribution of chronic HBV infection. http://www.cdc.gov/ncidod/diseases/ hepatitis/slideset/index.htm
  • CDC. Hepatitis B factsheet. http://www.cdc.gov/ncidod/diseases/ hepatitis/b/fact.htm

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.